135 related articles for article (PubMed ID: 26004008)
1. Targeting of the EGFR/β1 integrin connecting proteins PINCH1 and Nck2 radiosensitizes three-dimensional SCC cell cultures.
Rossow L; Eke I; Dickreuter E; Cordes N
Oncol Rep; 2015 Jul; 34(1):469-76. PubMed ID: 26004008
[TBL] [Abstract][Full Text] [Related]
2. EGFR/JIP-4/JNK2 signaling attenuates cetuximab-mediated radiosensitization of squamous cell carcinoma cells.
Eke I; Schneider L; Förster C; Zips D; Kunz-Schughart LA; Cordes N
Cancer Res; 2013 Jan; 73(1):297-306. PubMed ID: 23074283
[TBL] [Abstract][Full Text] [Related]
3. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures.
Eke I; Cordes N
Radiother Oncol; 2011 Jun; 99(3):279-86. PubMed ID: 21704406
[TBL] [Abstract][Full Text] [Related]
4. EGFR and β1-integrin targeting differentially affect colorectal carcinoma cell radiosensitivity and invasion.
Poschau M; Dickreuter E; Singh-Müller J; Zscheppang K; Eke I; Liersch T; Cordes N
Radiother Oncol; 2015 Sep; 116(3):510-6. PubMed ID: 26096850
[TBL] [Abstract][Full Text] [Related]
5. ILKAP, ILK and PINCH1 control cell survival of p53-wildtype glioblastoma cells after irradiation.
Hausmann C; Temme A; Cordes N; Eke I
Oncotarget; 2015 Oct; 6(33):34592-605. PubMed ID: 26460618
[TBL] [Abstract][Full Text] [Related]
6. Targeting FAK radiosensitizes 3-dimensional grown human HNSCC cells through reduced Akt1 and MEK1/2 signaling.
Hehlgans S; Eke I; Cordes N
Int J Radiat Oncol Biol Phys; 2012 Aug; 83(5):e669-76. PubMed ID: 22483702
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of EGFR or IGF-1R signaling enhances radiation response in head and neck cancer models but concurrent inhibition has no added benefit.
Raju U; Molkentine DP; Valdecanas DR; Deorukhkar A; Mason KA; Buchholz TA; Meyn RE; Ang KK; Skinner H
Cancer Med; 2015 Jan; 4(1):65-74. PubMed ID: 25355701
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of GRP78 abrogates radioresistance in oropharyngeal carcinoma cells after EGFR inhibition by cetuximab.
Sun C; Han C; Jiang Y; Han N; Zhang M; Li G; Qiao Q
PLoS One; 2017; 12(12):e0188932. PubMed ID: 29232380
[TBL] [Abstract][Full Text] [Related]
9. Simultaneous β1 integrin-EGFR targeting and radiosensitization of human head and neck cancer.
Eke I; Zscheppang K; Dickreuter E; Hickmann L; Mazzeo E; Unger K; Krause M; Cordes N
J Natl Cancer Inst; 2015 Feb; 107(2):. PubMed ID: 25663685
[TBL] [Abstract][Full Text] [Related]
10. α integrin targeting for radiosensitization of three-dimensionally grown human head and neck squamous cell carcinoma cells.
Steglich A; Vehlow A; Eke I; Cordes N
Cancer Lett; 2015 Feb; 357(2):542-8. PubMed ID: 25497870
[TBL] [Abstract][Full Text] [Related]
11. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
[TBL] [Abstract][Full Text] [Related]
12. Cetuximab-resistant oral squamous cell carcinoma cells become sensitive in anchorage-independent culture conditions through the activation of the EGFR/AKT pathway.
Ohnishi Y; Yasui H; Kakudo K; Nozaki M
Int J Oncol; 2015 Dec; 47(6):2165-72. PubMed ID: 26497980
[TBL] [Abstract][Full Text] [Related]
13. Cytotoxic properties of radionuclide-conjugated Cetuximab without and in combination with external irradiation in head and neck cancer cells in vitro.
Eke I; Ingargiola M; Förster C; Kunz-Schughart LA; Baumann M; Runge R; Freudenberg R; Kotzerke J; Heldt JM; Pietzsch HJ; Steinbach J; Cordes N
Int J Radiat Biol; 2014 Aug; 90(8):678-86. PubMed ID: 24597752
[TBL] [Abstract][Full Text] [Related]
14. EGFR status and EGFR ligand expression influence the treatment response of head and neck cancer cell lines.
Jedlinski A; Ansell A; Johansson AC; Roberg K
J Oral Pathol Med; 2013 Jan; 42(1):26-36. PubMed ID: 22643066
[TBL] [Abstract][Full Text] [Related]
15. Enhanced radiosensitivity of head and neck squamous cell carcinoma cells by β1 integrin inhibition.
Eke I; Dickreuter E; Cordes N
Radiother Oncol; 2012 Aug; 104(2):235-42. PubMed ID: 22748391
[TBL] [Abstract][Full Text] [Related]
16. Influence of epidermal growth factor receptor expression on the cetuximab and panitumumab response rates of head and neck carcinoma cells.
Hartmann S; Seher A; Brands RC; Linz C; Lessner G; Böhm H; Kübler AC; Müller-Richter UD
J Craniomaxillofac Surg; 2014 Oct; 42(7):1322-8. PubMed ID: 24780353
[TBL] [Abstract][Full Text] [Related]
17. Dual-agent molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR antibody with tyrosine kinase inhibitor.
Huang S; Armstrong EA; Benavente S; Chinnaiyan P; Harari PM
Cancer Res; 2004 Aug; 64(15):5355-62. PubMed ID: 15289342
[TBL] [Abstract][Full Text] [Related]
18. Combined epidermal growth factor receptor targeting with the tyrosine kinase inhibitor gefitinib (ZD1839) and the monoclonal antibody cetuximab (IMC-C225): superiority over single-agent receptor targeting.
Matar P; Rojo F; Cassia R; Moreno-Bueno G; Di Cosimo S; Tabernero J; Guzmán M; Rodriguez S; Arribas J; Palacios J; Baselga J
Clin Cancer Res; 2004 Oct; 10(19):6487-501. PubMed ID: 15475436
[TBL] [Abstract][Full Text] [Related]
19. The role of the focal adhesion protein PINCH1 for the radiosensitivity of adhesion and suspension cell cultures.
Sandfort V; Eke I; Cordes N
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20927395
[TBL] [Abstract][Full Text] [Related]
20. Signaling via PINCH: Functions, binding partners and implications in human diseases.
Xu H; Cao H; Xiao G
Gene; 2016 Dec; 594(1):10-15. PubMed ID: 27590440
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
